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Control of cytokine production by immune cells is pivotal for counteracting infections via
orchestration of local and systemic inflammation. Although their contribution has long been
underexposed, it has recently become clear that human Fc gamma receptors (FcγRs),
which are receptors for the Fc region of immunoglobulin G (IgG) antibodies, play a criti-
cal role in this process by controlling tissue- and pathogen-specific cytokine production.
Whereas individual stimulation of FcγRs does not evoke cytokine production, FcγRs cell-
type specifically interact with various other receptors for selective amplification or inhibition
of particular cytokines, thereby tailoring cytokine responses to the immunological context.
The physiological function of FcγR-mediated control of cytokine production is to coun-
teract infections with various classes of pathogens. Upon IgG opsonization, pathogens
are simultaneously recognized by FcγRs as well as by various pathogen-sensing recep-
tors, leading to the induction of pathogen class-specific immune responses. However,
when erroneously activated, the same mechanism also contributes to the development
of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.
In this review, we discuss control of cytokine production as a novel function of FcγRs in
human innate immune cells in the context of homeostasis, infection, and autoimmunity
and address the possibilities for future therapeutic exploitation.
Keywords: antibacterial response, cross-talk, dendritic cells, FcγRIIa, macrophages, rheumatoid arthritis, systemic
lupus erythematosus,TNFα
INTRODUCTION
Control of cytokine production is pivotal for controlling local and
systemic inflammation and is required for shaping both innate
and adaptive immune responses. Innate immune cells produce
cytokines upon detection of pathogens or endogenous danger
signals via activation of different families of receptors, which col-
lectively are referred to as pattern recognition receptors (PRRs).
The most well-known examples of PRRs are the families of toll-
like receptors (TLRs), C-type lectin receptors, NOD-like receptors,
and RIG-I-like receptors (1). However, the list of families of recep-
tors that can induce or modulate cytokine production is still
continuously expanding.
In the last 10 years, it has become apparent that also the fam-
ily of Fc gamma receptors (FcγRs), which are receptors for the
Abbreviations: ACPA, anti-citrullinated protein antibodies; ADCC, antibody-
dependent cellular cytotoxicity; CRP, C-reactive protein; DAMP, damage-associated
molecular pattern; DC, dendritic cell; FcγR, Fc gamma receptor; IgG, immunoglob-
ulin G; ITAM, immunoreceptor tyrosine-based activation motif; ITAMi, inhibitory
immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-
based inhibitory motif; IVIG, intravenous immunoglobulin; PAMP, pathogen-
associated molecular pattern; pDC, plasmacytoid dendritic cell; PRR, pattern
recognition receptor; RA, rheumatoid arthritis; SH(I)P-1, Src homology 2 domain-
containing (inositol) phosphatase-1; SLE, systemic lupus erythematosus; SNP, single
nucleotide polymorphism; SSc, systemic sclerosis; Syk, spleen tyrosine kinase; TLR,
toll-like receptor.
Fc region of immunoglobulin G (IgG) (2), plays a major role
in orchestrating cytokine production. FcγRs have long been
known to mediate a large variety of functions, such as anti-
gen or pathogen uptake, degranulation, antigen presentation, and
antibody-dependent cellular cytotoxicity (ADCC) [reviewed by
Nimmerjahn and Ravetch (3) and Guilliams et al. (4)]. In contrast,
their function in orchestrating inflammation by controlling the
production of cytokines has long been underexposed. When eval-
uating recent findings, it appears that FcγR-mediated control of
cytokine production is physiologically important to tailor immune
responses to efficiently counteract pathogens. However, when
activated undesirably, the same mechanism of FcγR-mediated
cytokine induction is responsible for excessive inflammation as
observed in autoimmune diseases that are associated with IgG
autoantibodies, such as rheumatoid arthritis (RA) and systemic
lupus erythematosus (SLE).
In general,most knowledge on FcγR biology comes from mouse
studies. Although various FcγR functions are conserved between
species, both IgG subclasses and FcγRs differ in a number of
aspects between mouse and man (5). These differences impede
translation of findings for particular FcγR features from mouse
studies to the human situation and vice versa. Importantly, the
capacity of FcγRs to induce or modulate cytokine production
appears to substantially differ between species, as summarized
in Box 1. This difference is likely to be caused by differential
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Box 1 FcγR-related differences between mouse and man.
The orchestration of cytokine responses by activating low-affinity FcγRs clearly differs between humans and mice. Four key differences in
this regard are summarized below.
• FcγRIIa, which is the main FcγR responsible for the induction of pro-inflammatory cytokine production by human cells, is not expressed
in mice (3–5).
• In various human cell types, including dendritic cells (DCs) and macrophages, stimulation with immune complexes induces FcγR-
dependent caspase-1 and inflammasome activation for the production of functional IL-β (6, 14, 45). In contrast, in mice, immune complexes
inhibit inflammasome activation and IL-1β production (93).
• In humans, the cytokine profile induced by cross-talk between activating FcγRs and co-receptors is predominantly characterized by various
pro-inflammatory cytokines, of whichTNFα upregulation is most pronounced (6, 7, 14, 45, 59–61, 71, 72). In contrast, the cytokine profile
induced by combined stimulation of murine DCs or macrophages with immune complexes and TLR ligands is characterized by elevated
IL-10 and abrogated IL-12 production, whereas TNFα production is not affected or even reduced (14, 93–98).
• In humans, FcγR-TLR cross-talk results in enhanced Th17 responses (6, 14), while in mice, FcγR co-stimulation promotes Th2 responses
(93, 96), which most likely results from the above mentioned differences in cytokine profiles by antigen-presenting cells.
expression of FcγRIIa, which is the main cytokine-inducing
receptor in humans, but has no direct homolog in mice (3–5).
In this review, we will therefore mainly focus on data from studies
using human cells or humanized mouse models and their relevance
to understanding and potential treatment of human diseases.
CONTEXT-DEPENDENT CYTOKINE PRODUCTION BY FcγRs
A key feature of FcγRs related to cytokine production is that FcγRs
are unable to directly induce cytokines themselves, but instead col-
laborate with other receptors to amplify or inhibit the production
of specific cytokines. The ultimate FcγR-mediated cytokine pro-
file is therefore not uniform, but instead appears to be tailored to
the immunological context in which FcγR stimulation takes place.
We here propose that this context-dependent cytokine production
mediated by FcγRs is achieved through regulation at (at least) four
levels.
First, the induced cytokine profile depends on the specific
receptor that FcγRs collaborate with. For example, cross-talk
between FcγRIIa and TLRs, as occurs upon recognition of
IgG opsonized bacteria, strongly amplifies production of pro-
inflammatory cytokines such as TNFα (6). In contrast, FcγRs
do not synergize with several cytokine receptors, including IL-6
receptor, IL-12 receptor, and IL-23 receptor (7). Second, the FcγR-
mediated cytokine response depends on the balance of activating
versus inhibitory FcγRs. Indeed, it has been shown that stimula-
tion of human DCs with IgG immune complexes simultaneously
conveys an inflammatory signal by triggering activating receptor
FcγRIIa and a tolerogenic signal by triggering inhibitory receptor
FcγRIIb (8). Disturbances of this balance between activating and
inhibitory FcγRs are associated with inflammation as observed
in patients with bacterial infections or RA (9–11). Third, FcγRs
are able to discriminate between aggregated (i.e., antigen-bound)
and soluble IgG, thereby adding another layer of complexity to
FcγR-mediated cytokine modulation. For example, while large
immune complexes are known to enhance cytokine production,
stimulation of FcγRs with soluble IgG, as occurs under home-
ostatic conditions, results in inhibitory signaling that attenuates
cytokine production (12, 13). Fourth, FcγR stimulation induces
cell-intrinsic cytokine responses, thereby enabling cell-type and
tissue-specific responses. For instance, while FcγR-TLR cross-talk
enhances IL-10 production by DCs or macrophages, it attenuates
IL-10 production by monocytes (7). In this review, we will summa-
rize and discuss these four levels of regulation of FcγR-mediated
cytokine production by human innate immune cells in the con-
text of three immunological states: homeostasis, infection, and
autoimmunity.
HOMEOSTASIS: INHIBITION OF CYTOKINE RESPONSES BY
FcγRs
In humans, three different FcγR classes exist, which are FcγRI
(CD64), FcγRII (CD32), and FcγRIII (CD16; see Figure 1). FcγRI
is the only high-affinity receptor, indicating that it is able to bind
monomeric IgG molecules. In contrast, all other FcγRs are low-
affinity receptors and therefore require high-avidity binding by
IgG immune complexes for appropriate binding and signaling
(2–4). FcγRI, FcγRIIa, FcγRIIc (expressed only in a minority of
individuals), FcγRIIIa, and FcγRIIIb are categorized as activat-
ing receptors, which mostly signal via so-called immunorecep-
tor tyrosine-based activation motifs (ITAMs). These ITAMs are
situated either in their FcγR cytoplasmic tail (FcγRIIa, FcγRIIc)
or in adaptor proteins such as the common γ-chain. In contrast,
FcγRIIb is the only known inhibitory FcγR, which contains an
immunoreceptor tyrosine-based inhibitory motif (ITIM) (3, 4).
Fc gamma receptors are widely expressed in virtually all
hematopoietic cells, except for T cells. Most of these cells express
both activating and inhibitory FcγRs, with the exception of NK
cells (expressing solely FcγRIII) and B cells (expressing solely
FcγRIIb) (3). Focusing on myeloid cells, monocytes express high
levels of FcγRI and FcγRIIa, whereas FcγRIIb is moderately
expressed and FcγRIII is expressed only on a subset of monocytes
(4, 7). Both monocyte-derived DCs and DCs from blood express
primarily FcγRIIa and FcγRIIb (4, 6–8). Macrophages express all
classes of FcγRs, but particularly express high levels of FcγRIIa (4,
7, 14). In contrast, plasmacytoid DCs (pDCs) express FcγRs only
at very low levels (4, 8). Here, we will first discuss the role of both
inhibitory and activating FcγRs in homeostasis.
FcγRIIb-MEDIATED INHIBITION OF CYTOKINE PRODUCTION
Important for the control of cytokine production under
homeostatic conditions is the balance between activating and
inhibitory FcγRs. Studies in mice identified FcγRIIb as the
main inhibitory receptor for various FcγR-mediated processes
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FIGURE 1 |The family of human FcγRs. Human FcγRs are divided into
three types: FcγRI, FcγRII, and FcγRIII. These receptors can be grouped
by function (FcγRIIb is the only inhibitory receptor, whereas the other
receptor are activating) or affinity to IgG (FcγRI is the only high-affinity
receptor). For most of the FcγRs, SNPs are known that affect their affinity
to IgG isotypes.
(3). ITIM-containing receptors, including FcγRIIb, perform their
inhibitory functions via recruitment of phosphatases, specifically
Src homology 2 (SH2) domain-containing phosphatase-1 (SHP-
1) and SH2 domain-containing inositol phosphatase-1 (SHIP-1).
These phosphatases are able to impede effector functions of ITAM-
bearing receptors, including activating FcγRs, by interfering with
activation of a variety of kinases and adaptor proteins (15, 16).
The research on human FcγRIIb took a leap forward upon
the development of a specific FcγRIIb-blocking antibody (8).
Studies using human monocytes or DCs demonstrated that stim-
ulation with IgG immune complexes, which simultaneously stim-
ulate both activating and inhibitory FcγRs, hardly induce the
production of any cytokines (6, 8, 17–19). In contrast, selective
blockade of FcγRIIb under these conditions induces production
of numerous cytokines and chemokines, including TNFα, IL-1β,
IL-6, IL-8, IL-12p70, and IL-23 (8, 18, 20), which consequently
promotes T-cell responses (8). These data demonstrate that the
balance between activating and inhibitory FcγRs (schematically
depicted in Figure 2A) effectuates a threshold for cell activation
and consequent immune responses.
Regulation of this balance critically depends on the rela-
tive cell surface expression of activating and inhibitory FcγRs,
which in turn is dictated by factors in the direct surround-
ings of the immune cells. Exposure to soluble, monomeric IgG,
as occurs under homeostatic conditions, selectively reduces the
expression of FcγRIIa on human DCs, thereby shifting the bal-
ance toward anti-inflammatory responses induced by inhibitory
FcγRIIb (Figure 2A). In contrast, exposure to IFNγ, as occurs
under inflammatory conditions, results in decreased FcγRIIb and
increased FcγRI and FcγRIIa expression, thereby tilting the bal-
ance toward the induction of inflammatory cytokine production
(8). Taken together, ITIM-containing FcγRIIb has a crucial role in
regulating inflammatory responses under homeostatic conditions.
ITAMi: INHIBITORY SIGNALING INDUCED BY CIRCULATING IgG
Although inhibitory signals were initially only associated with
FcγRs that bear an ITIM (i.e., solely FcγRIIb) in the last decade,
it has become clear that also ITAM-related receptors can neg-
atively control inflammatory responses. This additional, anti-
inflammatory function of ITAMs has been denoted inhibitory
ITAM (ITAMi) (16, 21). It has recently been shown that circu-
lating IgG monomers, as abundantly present in serum, induce
ITAMi signaling by binding to human low-affinity receptors
FcγRIIa (13) and FcγRIII (12). Besides inhibiting TLR-induced
calcium responses, endocytosis, phagocytosis, and reactive oxy-
gen species production, this ITAMi signaling also inhibits the
production of pro-inflammatory cytokines and chemokines by
human monocytes or macrophages, including TNFα, IL-6, and
IL-8 (12, 13) (Figure 2B). Similar to ITIM-mediated inhibi-
tion, ITAMi-mediated inhibition requires SHP-1 recruitment (16).
Subsequently, so-called inhibisomes are being formed, which are
clusters containing FcγRs together with other receptors that are
being inhibited, such as TLRs (12, 22). In addition, it has been
described that small, soluble IgG complexes enhance TLR-induced
anti-inflammatory IL-10 production by various subsets of human
macrophages, whereas pro-inflammatory cytokines are not or
hardly affected (23). However, it is yet unclear whether this elevated
IL-10 production truly depends on ITAMi signaling.
In summary, FcγRs play an active role in the regulation
of homeostasis, which is achieved by suppression of pro-
inflammatory cytokine responses as well as promotion of IL-
10 production via both inhibitory receptor FcγRIIb and ITAMi
signaling of activating FcγRs.
INFECTION: INDUCTION OF PRO-INFLAMMATORY
CYTOKINES BY FcγRs
Whereas FcγRs suppress pro-inflammatory cytokines under
homeostatic conditions, they are crucial in promoting inflamma-
tion upon infection. The ultimate immune response by myeloid
cells induced in response to pathogens is not the result of stim-
ulation of one single receptor, but rather is induced by cross-talk
or collaboration between multiple receptors (24, 25). This col-
laboration between receptors induces an intricate regulation of
cytokine production that effectuates pathogen- and tissue-specific
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FIGURE 2 | FcγRIIa/b expression and FcγR-mediated control of cytokine
production during homeostasis, infection, and autoimmunity. (A)The
balance of expression levels of activating FcγRIIa (IIa) and inhibitory FcγRIIb
(IIb) is skewed toward FcγRIIb expression under homeostatic conditions,
whereas it is skewed toward FcγRIIa under conditions of infection or
autoimmunity (note: data on FcγR expression in RA patients are not fully
consistent, see main text). (B) FcγRs orchestrate cytokine production under
different conditions. Homeostasis: pro-inflammatory cytokine production is
inhibited via either ITIM-mediated signaling via SHP-1 (or SHIP-1) downstream
of FcγRIIb or ITAMi-mediated signaling downstream of activating FcγRs such
as FcγRIIa. Infection: in the context of bacterial infections, specific
pro-inflammatory cytokines are synergistically being upregulated (via
upregulation of both transcription and caspase-1 activation) as a result of
cross-talk between FcγRIIa and TLRs. For viral infections, the effect of
simultaneous stimulation of FcγRs and TLRs recognizing viral structures on
cytokine production is not yet clear. Autoimmunity : in RA, simultaneous
stimulation of FcγRIIa (via IgG autoantibody-containing immune complexes)
and TLRs (via disease-associated DAMPs) induces cross-talk similar to that
upon bacterial infection, which results in synergistic upregulation of specific
pro-inflammatory cytokines in a Syk-dependent manner. In the context of
SLE, disease-associated immune complexes are being taken up by pDCs in
an FcγRIIa-dependent manner and subsequently delivered to TLR9-containing
lysosomes, which results in upregulation of production of type I interferons
and pro-inflammatory cytokines.
immunity and prevents unbridled responses with detrimental
effects.
Initially only PRRs, which recognize conserved microbial struc-
tures known as pathogen-associated molecular patterns (PAMPs),
were considered to be able to induce innate response genes such
as cytokines (26). However, recently it has become clear that also
FcγRs play a major role in control of cytokine production. Due
to the high levels of IgG directed against numerous antigens,
invading pathogens are efficiently opsonized when they penetrate
the body’s barriers, either directly during primary infection or at a
later stage after generation of pathogen-specific IgG. Thus, in con-
trast to homeostatic conditions were IgG molecules are present in
monomeric form, pathogen opsonization results in the formation
of IgG complexes which can activate low-affinity receptors such as
FcγRIIa. Consequently, innate immune cells sense these opsonized
pathogens via PRRs and FcγRs simultaneously. Although FcγRs
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do not directly induce pro-inflammatory cytokines when stim-
ulated individually (6, 8, 17–19), combined stimulation of FcγRs
together with other receptors results in pathogen-specific cytokine
responses. Below,we will discuss the role of FcγR-induced cytokine
production in response to infection with different classes of
pathogens.
BACTERIAL INFECTIONS
Immunoglobulin G seems to particularly play an important role
in defense against bacteria, as patients with primary antibody
deficiencies mainly suffer from bacterial infections, but hardly
from fungal or viral infections (27). In healthy individuals, high
amounts of cross-reactive IgG directed to bacterial antigens are
present and consequently bacteria are efficiently being opsonized,
even during primary infection (6). Importantly, FcγRII expression
on monocytes and neutrophils is increased in patients with bacte-
rial infections, compared to healthy controls or patients with viral
infections (11). In addition, stimulation of TLR2 or TLR4, which
predominantly recognize bacterial PAMPs, has been described to
induce FcγRIIa expression on human monocytes (28). These find-
ings indicate that exposure to bacteria makes myeloid cells more
prone to recognize complexed IgG structures such as opsonized
bacteria (Figure 2A).
Recent data show that cytokine induction by FcγRIIa plays an
important role in directing antibacterial responses. IgG opsoniza-
tion of various bacteria such as Staphylococcus aureus or Klebsiella
pneumoniae strongly increases the production of particular pro-
inflammatory cytokines by DCs, such as IL-1β, IL-6, IL-23, and
TNFα, but not IL-12 (6). Induction of this specific cytokine pro-
file skews T helper cell responses toward Th17, which is required
for efficient eradication of extracellular pathogens and therefore
appears to function as a natural mechanism to counteract bacter-
ial infections. This synergistic cytokine response fully depends on
cross-talk between FcγRIIa and TLRs, which are activated simul-
taneously on DCs upon encountering IgG opsonized bacteria.
Mechanistically, FcγRIIa-TLR cross-talk in DCs is mediated by
both enhancing the transcription of specific cytokine genes and
via activation of caspase-1, which cleaves pro-IL-1β into its bioac-
tive form (6). Besides DCs, FcγRIIa-TLR cross-talk also occurs
in human monocytes and macrophages (7), indicating that this
antibacterial mechanism is functional in multiple myeloid cell
types (Figure 2B). In addition, several reports suggest that FcγRs
and TLRs do not necessarily need to be activated simultaneously
for this synergistic effect, since overnight activation of monocytes
or DCs followed by stimulation with aggregated IgG still strongly
increases TNFα production (10, 28, 29).
Monocytes exposed to IFNγ appear to have an additional,
indirect mechanism of immune complex-dependent cytokine pro-
duction. Upon LPS stimulation, exposure of these cells to immune
complexes downregulates IL-10 receptor expression and inhibits
IL-10 signaling in an FcγRI-dependent manner, which results in
enhanced TNFα and IL-6 production (30). Importantly, this IL-10
loop was only observed in monocytes polarized in the presence of
IFNγ, which induces FcγRI expression, but not upon M-CSF-
induced differentiation (30), which stresses the importance of
cytokines and differentiation factors in the micro-environment
of immune cells for FcγR-mediated effects.
The importance of FcγRIIa in antibacterial responses is further
emphasized by studies on the FCGR2A single nucleotide polymor-
phism (SNP) H131R. This SNP strongly affects binding affinity of
the receptor to IgG2, the main isotype that is reactive to bacterial
antigens (31). Multiple studies [reviewed by Van Sorge et al. (32)]
indicate that FCGR2A-R131 homozygous individuals, carrying the
receptor with low IgG2 affinity, are more susceptible to bacterial
infections. However, this difference is unlikely to be caused by dif-
ferences in FcγR-induced cytokine production, since FcγRIIa-TLR
cross-talk is completely functional in DCs from FCGR2A-R131
homozygous individuals (7). Instead, this difference in suscepti-
bility to bacterial infections may be explained by the finding that
FCGR2A-R131 impairs IgG2-mediated phagocytosis (33). Appar-
ently, while the low affinity for IgG2 of FcγRIIa-131R impairs
uptake of opsonized bacteria, the binding of large IgG2 complexes
is still sufficient to induce cytokines. This finding strengthens the
idea that FcγRIIa-mediated cytokine production and uptake are
regulated via distinct mechanisms.
The relevance of FcγR-mediated cytokine responses in combat-
ing bacteria is also indirectly indicated by the existence of immune
escape mechanisms to evade this response. Interestingly, Strepto-
coccus pyogenes produces Endoglycosidase S, an enzyme that is able
to hydrolyze the heavy chain glycan of IgG molecules. As a result,
the binding of IgG to FcγRIIa was strongly reduced (34), which
impairs the antibacterial immune response. Additionally, S. aureus
secretes a potent FcγRII antagonists, formyl peptide receptor-like
1 inhibitor (FLIPr) that competitively blocks IgG binding and
subsequent IgG-mediated antibacterial effector functions (35).
Notably, FcγR-dependent control of cytokine production may
not only depend on the presence of IgG. Also, members of the
pentraxin family such as C-reactive protein (CRP) are known to
interact with FcγRs. CRP is an acute-phase protein that is rapidly
synthesized by the liver upon injury or infection and it is known to
bind phosphocholine that is expressed on the surface of particular
bacteria (36). It has been reported that CRP increases cytokine pro-
duction, predominantly TNFα and IL-1β, by PBMC in response
to S. pneumoniae via FcγRI and FcγRIIa (37).
In conclusion, FcγRs are critically involved in counteract-
ing bacterial infections. Particularly, cross-talk between FcγRIIa
and bacterial component recognizing TLRs in human myeloid
cells selectively promotes the production of pro-inflammatory
cytokines that play a crucial role in antibacterial immunity, such
as TNFα and various Th17-promoting cytokines.
FUNGAL INFECTIONS
In contrast to bacterial infections, currently still little is known
about the contribution of FcγRs to cytokine production in anti-
fungal immune responses. However, it is known that opsonization
of Candida albicans synergistically increases the production of
TNFα by human monocytes or PBMC. This effect was largely
dependent on extracellular signal-regulated kinases (ERK) (38).
Fungi are recognized through multiple PRRs, including TLRs and
C-type lectin receptors. Dectin-1 is one of the main cytokine-
inducing C-type lectin receptors, which strongly contributes to
antifungal immunity (26). However, FcγR co-stimulation with
immobilized IgG does not enhance Dectin-1-induced TNFα pro-
duction (7). This indicates that increased TNFα production upon
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exposure to opsonized C. albicans is likely to be dependent on
cross-talk of FcγRs with TLRs, rather than with C-type lectin
receptors. Furthermore, it strengthens the concept that FcγR stim-
ulation does not simply enhance cytokine production induced
by any given receptor, but instead specifically collaborates with
particular (families of) receptors.
VIRAL INFECTIONS
The main focus of research on the role of antibodies and FcγRs
during viral infections has been on virus neutralization, ADCC,
antibody-dependent enhancement of infection, and phagocytosis,
while data on FcγR-mediated cytokine responses in the context
of viral infections is limited as well as conflicting. Recently, it
has been shown that monocytes, DCs, and macrophages strongly
upregulate TNFα and IL-6 production upon exposure to serum-
opsonized Dengue virus, in an FcγRIIa-dependent manner (39).
This is likely to be due to cross-talk of TLR3 and TLR7/8, recog-
nizing virus-associated double-stranded or single-stranded RNA
respectively, with FcγRIIa, as has been described recently (7). Oth-
ers have confirmed upregulation of IL-6, as well as IL-10, upon
serum-opsonized Dengue virus in a human monocytic cell line on
both mRNA and protein level (40–42). In contrast, TNFα as well
as IL-12 were reported to be downregulated in this assay (40).
Besides pro-inflammatory cytokines such as TNFα and IL-6,
other cytokines and chemokines, particularly type I interferons
and related chemokines, may be of great relevance in the context
of viral infections (43). However, the effect of FcγRIIa (co-)ligation
on these specific cytokines and chemokines has hardly been
studied. The scarce data on this topic is not conclusive, as one
study showed upregulation of IFNα and IFNβ by macrophages
upon stimulation with opsonized Dengue virus (39) while oth-
ers reported downregulation of IFNβ protein by a monocytic cell
line upon Dengue opsonization (42). Interestingly, Posch and col-
leagues recently reported that exposure of DCs to opsonized HIV
results in a decreased HIV-specific CD8+ T-cell response, in an
FcγRIIa-dependent way. However, to which extent this effect was
dependent on cytokines produced by DCs has not been studied
(44). In conclusion, the role of FcγRs in cytokine production
during viral infections (Figure 2B), and to what extend cytokine
modulation is beneficial to the host or to the virus, is not yet clear.
PARASITIC INFECTIONS
Recently, it was shown that erythrocytes infected with malaria-
causing Plasmodium falciparum promote pro-inflammatory
cytokines once opsonized with IgG. Particularly, opsonized
infected erythrocytes, compared to unopsonized cells, induce
high TNFα, IL-1β, and IL-6 production by human macrophages
(45). Remarkably, the role of TNFα and other pro-inflammatory
cytokines in parasitic infections, including P. falciparum, is
ambiguous: TNFα has been identified to promote parasite killing,
but it also contributes to development of severe malaria dis-
ease (46). Interestingly, the upregulation of pro-inflammatory
cytokines was not transcriptionally regulated (45), in contrast to
what was observed in DCs in response to opsonized bacteria (6).
Induction of IL-1β upon exposure to opsonized infected erythro-
cytes was shown to be the result of FcγR-induced inflammasome
activation (45), which is in agreement with previous studies using
both DCs and M2 macrophages (6, 14). Although data on FcγR-
mediated cytokines in antiparasitic responses is limited, it appears
that similar to bacterial infections, IgG opsonization promotes
specific pro-inflammatory cytokines upon parasitic infection.
AUTOIMMUNITY: UNDESIRED FcγR-INDUCED CYTOKINE
PRODUCTION
Although collaboration of FcγRs with other receptors to promote
cytokine responses is beneficial in combating infections, undesired
activation of this mechanism may contribute to the development
of autoimmunity. RA, SLE, and several other autoimmune dis-
eases are characterized by the presence of IgG autoantibodies and
FcγR involvement in pathogenesis (47–49). In these diseases, IgG
autoantibody-containing immune complexes can function as a
danger signal that activates innate immune cells. We will here dis-
cuss the evidence of FcγR-mediated cytokine production in the
context of several autoimmune diseases.
RHEUMATOID ARTHRITIS
RA is a chronic autoimmune disease occurring in 1% of the pop-
ulation and is characterized by inflammation and damage of the
joints (50). Although the pathogenesis of RA is far from fully
understood, it is clear that pro-inflammatory cytokines, predomi-
nantly TNFα, have a crucial role in the inflammatory process, as is
emphasized by the great clinical improvement after neutralization
of these cytokines (50). In recent years, the presence of autoan-
tibodies, which is one of the hallmarks of RA, is beginning to
be recognized as a contributing factor in inflammation and joint
damage via the production of pro-inflammatory cytokines. The
most prominent type of autoantibodies present in RA patients is
anti-citrullinated protein antibodies (ACPA), which are present
long before onset of disease symptoms and are mainly of the IgG
isotype (49, 51, 52). Upon recognition of their antigen, e.g., citrul-
linated extracellular matrix proteins in the joint, autoantibodies
form large, insoluble, and amorphous immune complexes (52)
that enable their recognition by low-affinity FcγRs.
The importance of FcγRs in RA pathogenesis is indicated by
various studies using mouse models for arthritis [reviewed by
El Bannoudi et al. (49)], of which the use of human FcγRIIa
transgenic mice may be the most relevant (53). These transgenic
mice display a higher susceptibility to collagen-induced arthri-
tis and developed more severe arthritis than wild-type mice (53,
54). Importantly, in a passive antibody transfer model, all FcγRIIa
transgenic mice develop arthritis, while none of the control ani-
mals are affected. In addition, these transgenic mice spontaneously
develop multi-organ autoimmunity (53).
In the context of RA, FcγR stimulation on myeloid cells has
been shown to induce pro-inflammatory cytokines that are pivotal
in RA pathogenesis, including TNFα, IL-1β, and IL-6. Precipi-
tated or plate-bound IgG from serum or synovial fluid of RA
patients, without any additional stimulus, induces TNFα produc-
tion by healthy donor PBMC, predominantly monocytes, in an
FcγRIIa-dependent manner (55–57). However, in these experi-
ments, the resulting levels of TNFα were rather low (picogram-
range), which indicates the marginal capacity of FcγRs to induce
cytokine production when stimulated without any co-stimulation.
Similar to their role in pathogen defense, FcγRs essentially need
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to collaborate with other families of receptors for the induction of
physiological relevant cytokine responses. In RA synovia, this“sec-
ond signal” most likely originates from the family of TLRs. Besides
recognition of pathogens, TLR activation can occur through
recognition of endogenous ligands, also referred to as damage-
associated molecular patterns (DAMPs). These are abundantly
present in RA synovia as a result of tissue damage and cell
death (58). Indeed, activation of macrophages with IgG immune
complexes-containing citrullinated fibrinogen, which activates
both FcγRIIa and TLR4, strongly induces the production of TNFα
(59–61) (Figure 2B). A similar effect of FcγRIIa-TLR cross-talk
has been observed in human mast cells, which results in synergistic
upregulation of IL-8 production (62).
In addition, FcγR-TLR cross-talk may promote inflamma-
tion in RA patients by interfering with the immunosuppres-
sive function of M2 macrophages. Although macrophages are a
heterogeneous population of cells that can differentiate into a
full spectrum of different phenotypes, macrophages are generally
being categorized into either M1 macrophages, which are classi-
cally activated macrophages with pro-inflammatory properties,
or M2 macrophages, which display anti-inflammatory, regula-
tory, and/or wound healing properties. Importantly, while M2
macrophages are known to suppress inflammation in disorders
such as tumor formation, atherosclerosis, and obesity (63), in
RA patients FcγR-TLR cross-talk converts M2 macrophages to
promote inflammation (14). While the general phenotype of
M2 macrophages is retained, stimulation of these cells with IgG
immune complexes and TLR ligands induces the selective induc-
tion of RA-associated cytokines TNFα, IL-1β, and IL-6, and pro-
motes Th17 responses, in a spleen tyrosine kinase (Syk)-dependent
way (14). Since the conventional function of M2 macrophages,
i.e., preventing disproportionate immune activation and medi-
ating tissue repair, is abrogated, this may thereby contribute to
excessive inflammation as observed in RA patients.
Considered the importance of the balance of activating versus
inhibitory FcγRs in controlling inflammation, numerous studies
have investigated FcγR expression levels on immune cells of RA
patients. However, the data on this are far from consistent. Some
studies found no differences between RA patients and healthy
controls (60, 64–66), whereas others reported that monocytes, mo-
DCs, monocyte-derived macrophages, and synovial macrophages
of RA patients displayed elevated levels of activating receptors
FcγRIIa and FcγRIII, while expression of inhibitory receptor
FcγRIIb was similar to healthy controls (9, 10, 29, 57, 67, 68)
(Figure 2A). The reasons for these inconsistent findings are still
unclear, but may involve differences in the stage of disease, donor
variation, and disease heterogeneity.
Taken together, the body of evidence for a causative role of
FcγRs, predominantly in synergy with TLRs, in the induction
of inflammation in RA is increasing. As such, these data sup-
port the concept that the occurrence of IgG autoantibodies is not
merely an epiphenomenon, but in fact actively contributes to RA
pathogenesis.
SYSTEMIC LUPUS ERYTHEMATOSUS
Another well-known IgG immune complex associated autoim-
mune disease is SLE. SLE is a chronic, systemic autoimmune
disease that can affect virtually any organ, but primarily kidneys,
skin, lungs, brain, and heart. SLE is characterized by autoantibod-
ies to DNA, RNA, and other nuclear structures. The key cytokine
in the inflammatory process in SLE is considered to be IFNα,
which is mainly produced by pDCs (48, 69). A meta-analysis cov-
ering 17 studies revealed that FCGR2A-R131 is a significant risk
factor for SLE (70), suggesting FcγRIIa is involved in SLE patho-
genesis. Furthermore, it is known that ligation of TLR7 and 9,
which are endosomal receptors that recognize RNA and DNA
structures and are constitutively expressed by pDCs, induces IFNα
production. The localization of TLR7 and 9 in the endosomal
compartment ensures that under physiological conditions, these
TLRs are shielded from self-RNA or self-DNA at the exterior of
cells, for example from dying cells (69).
FcγRIIa has been shown to be important in inducing IFNα in
SLE patients,via cooperation with TLRs. Means and colleagues ele-
gantly showed that FcγRIIa facilitates uptake of DNA-containing
immune complexes and delivery to intracellular lysosomes com-
prising TLR9 in human pDCs (71). This FcγRIIa-dependent acti-
vation of TLR9 results in production of IFNα, as well as other
cytokines and chemokines such as TNFα, IL-1β, IL-6, and IL-8 (71,
72) (Figure 2B). Interestingly, this mechanism of FcγRIIa-induced
upregulation of cytokines in pDCs differs from that in other cell
types. While in pDCs the amplification of TLR-induced cytokine
production critically depends on FcγRIIa-dependent uptake of
immune complexes (71), cytokine production by FcγRIIa in DCs
and macrophages is independent of uptake (6, 14). Thus, although
via a different mechanism and in a different cell-type than in
RA, FcγRIIa also contributes to the pathogenesis of SLE via
amplification of cytokine production.
SYSTEMIC SCLEROSIS
Systemic sclerosis (SSc) or scleroderma is a heterogeneous autoim-
mune connective tissue disease of unknown etiology, which
is characterized by excessive fibrosis in the skin and internal
organs, vasculopathy, and immune abnormalities. Autoantibod-
ies are present in more than 95% of SSc patients, which are
directed against a variety of nuclear, cytoplasmic, and extracellular
autoantigens (73). In addition, SSc is characterized by the release
of endogenous TLR ligands, which form immune complexes by
the binding of autoantibodies (74). Reminiscent of what has been
observed in pDCs for SLE immune complexes (71), stimulation
with SSc immune complexes induces IFNα production by PBMC,
which is dependent on FcγRII-mediated uptake of immune com-
plexes and the presence of RNA, suggesting involvement of TLR7
(75). Similar to SLE, this mechanism may contribute to the IFN
type gene “signature” as observed in many SSc patients (76).
OTHER AUTOIMMUNE DISEASES
Besides RA,SLE,and SSc,FcγR-dependent modulation of cytokine
production may play a role in the pathogenesis of several
other disorders characterized by IgG autoantibodies. In princi-
ple, FcγR-TLR cross-talk can be induced in any disorder involving
immune complexes, endogenous TLR ligands, and FcγR- and
TLR-expressing immune cells. Although there is little direct evi-
dence, several diseases are likely to fulfill these criteria, including
Sjögren’s syndrome, pemphigus, and multiple sclerosis (77–80).
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Future studies are required to elucidate whether and to what extent
FcγR-mediated cytokine production indeed is involved in these
autoimmune diseases.
MODULATION OF FcγR-INDUCED CYTOKINE PRODUCTION:
OPPORTUNITIES FOR THERAPEUTIC INTERVENTION
We have discussed that stimulation of FcγRs with IgG immune
complexes, predominantly in cooperation with PRRs such as TLRs,
promote inflammatory cytokine responses. On one hand, this
is beneficial to the host, since it allows us to efficiently coun-
teract infections with bacteria and possibly also other classes of
pathogens. On the other hand, activation of this mechanism can
also have detrimental effects, since it may promote inflamma-
tory responses leading to autoimmunity. Therefore, modulation of
FcγR-induced cytokine production in the context of infection and
autoimmunity may provide opportunities for therapeutic inter-
vention, either by reducing or by enhancing these inflammatory
responses.
An important example of FcγR-related therapy is the use of
intravenous immunoglobulin (IVIG). IVIG was initially used as
an IgG replacement therapy for immunocompromised patients,
but paradoxically also has general anti-inflammatory effects. Our
understanding of the anti-inflammatory effect of IVIG is still far
from complete and is beyond the scope of this review. Excellent
reviews by others (81, 82) summarize several modes of action
of IVIG in autoimmunity, including blockade of interaction of
immune complexes with activating low-affinity FcγRs. Moreover,
IVIG administration modulates the balance between activating
and inhibitory FcγRs, predominantly as a result of increased
expression of inhibitory receptor FcγRIIb (81, 82). In addition,
recently it has been described that IVIG preparations contain
anti-FcγRII and anti-FcγRIII antibodies (83), which may interfere
with binding of these FcγRs to disease-associated autoantibody
structures.
An alternative approach to interfere with FcγR-mediated
inflammation is to specifically provide IgG molecules that pref-
erentially bind to and activate the inhibitory receptor FcγRIIb.
Indeed, recently an anti-CD19 antibody carrying an Fc region with
over 400 times greater affinity to FcγRIIb compared to FγRIIa has
been engineered (84). Co-engaging of the B-cell receptor complex
together with FcγRIIb by this engineered antibody suppressed
B-cell activation and function, including IgG secretion and IL-
6 production (85–87), which therefore may be of therapeutic
benefit in IgG-mediated autoimmune diseases such as RA and
SLE.
Moreover, it may be promising to specifically interfere with
downstream molecules involved in FcγR-modulated cytokine pro-
duction. Although the mechanism of FcγR-modulated cytokine
production is still largely unidentified, Syk is known to be pivotal
for cytokine production induced by FcγRIIa-TLR cross-talk (14).
Interestingly, therapeutic inhibition of Syk using oral small mol-
ecule inhibitor R788 indeed significantly reduces disease activity
in RA patients (88). Although Syk is probably also required for
other immunological processes, these trials illustrate the potential
therapeutic possibilities of interfering with FcγR-induced cytokine
production. Similarly, identification of other key signaling mole-
cules of FcγR cross-talk in the future may give rise to additional
targets for therapy that could be blocked using small molecule
inhibitors.
While inhibition of FcγR-induced cytokine production may be
beneficial to attenuate inflammation in autoimmunity, enhancing
inflammation may be useful in the context of bacterial infections
or solid tumors. Considered its ability to amplify the induction of
Th17 responses by antigen-presenting cells such as DCs, an adju-
vant that would simultaneously cross-link activating low-affinity
FcγRs and TLRs may function as a powerful new vaccination
strategy for establishing effective antibacterial memory responses.
In addition, during both chronic bacterial infections and solid
tumors, the local environment is dominated by the presence of
anti-inflammatory or suppressive M2 macrophages, which atten-
uate the generation of effective antibacterial or antitumor immune
responses (63, 89, 90). As FcγR-TLR cross-talk is known to elicit
pro-inflammatory cytokine responses by M2 macrophages (14),
local induction of this response may greatly enhance the induc-
tion of antitumor immunity. Since IgG antibody therapy is already
used for the treatment of solid tumors (91), the coupling of TLR
agonists to these IgG antibodies for the local induction of inflam-
mation may be a very useful tool to further enhance the efficacy
of current treatments.
Taken together, additional knowledge on the specific cytokine
profile induced by different cell types and the identification of
the underlying molecular mechanisms are promising subjects for
future research, since this may lead to novel therapeutic strate-
gies for a large variety of disorders, including chronic (bacterial)
infections, tumor formation, and IgG autoantibody-associated
autoimmune diseases.
CONCLUDING REMARKS
Here, we have described and discussed a novel function of human
FcγRs in shaping cytokine responses and thereby orchestrat-
ing context-dependent immunity. Although the cytokine profile
induced by stimulation of activating FcγRs varies depending on
the cell-type and the combination of stimuli, it appears that TNFα
is the key cytokine that is being upregulated in almost all cell
types in response to FcγR co-stimulation. An important remain-
ing question is the identity of the (classes of) receptors are able
collaborate with FcγRs for the amplification (or inhibition) of
cytokine production. Thus far, FcγRs have been shown to syner-
gize with TLRs, IFNγ receptor, and IL-1 receptor, but not with
various other cytokine receptors or C-type lectins (7). Alterna-
tively, besides FcγRs also other classes of Fc receptors, including
FcεR and FcαR, may affect cytokine production upon collabo-
ration with PRRs or other receptors (92). Further identification
of collaborating and non-collaborating receptors will offer new
insights into the shaping of cytokine responses by myeloid cells
and thereby may provide new perspectives for future therapies.
While in this review we have completely focused on the cytokine
shaping properties of FcγRs, it is important to realize that FcγRs
are responsible for many other processes, including uptake, anti-
gen presentation, and ADCC. Therefore, in view of vaccination
or other therapeutic strategies, it would be useful to specifically
interfere with one aspect of FcγR-mediated effects, while leaving
other functions intact. In this regard, the recent findings that indi-
cate that FcγR-mediated phagocytosis and cytokine production
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are regulated via distinct mechanisms may provide valuable clues.
However, to fully exploit these differences, more knowledge about
mechanistic properties of these different FcγR functions in the
human immune system is required.
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